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Despite research efforts, cell uptake processes determining siRNA silencing efﬁciency remain unclear.
Here, we examine the relationship between in vitro cell culture models, cellular trafﬁcking and siRNA
silencing efﬁciency to provide a mechanistic insight on siRNA delivery system design. Model siRNA-
polyplexes, based on chitosan as a ‘classical’ condensing agent, were applied to a panel of lung epithe-
lial cell lines, H1299, A549 and Calu-3 and cell internalization levels, trafﬁcking pathways and gene
silencing assessed on exposure to pharmacological inhibitors. The data reveal striking differences in the
internalization behaviour and gene silencing efﬁciency in the tested cell lines, despite their common lung
epithelial origins. The model system’s silencing was lower where clathrin internalization pathway pre-
dominated in Calu-3, relative to silencing in H1299 cells where a non-clathrin internalization appears
dominant. Increased silencing on endosomal disruption was apparent in Calu-3 cells, but absent when
cellular internalization was not predominantly clathrin-mediated in A549 cells. This highlights that
identifying cell trafﬁcking pathways before incorporation of functional components to siRNA delivery
systems (e.g. endosomolytic compounds) is crucial. The study hence stresses the importance of selection
of appropriate cell culture model, relevant to in vivo target, to assess the gene silencing efﬁciency and
decide which functionalities the ‘stratiﬁed siRNA silencing vector’ requires.
© 2016 Published by Elsevier Inc.1. Introduction
Small interfering RNA (siRNA)-based therapeutics hold promise
in the management of a wide variety of diseases, but their full
potential rests on development of clinically suitable delivery car-
riers [1]. Understanding the cell entry processes of siRNA delivery
systems is essential in enabling the prediction, design and opti-
mization of transfection efﬁciency. The cell entry pathway of a
delivery system is likely to affect intracellular processing and hence
the silencing efﬁciency. Despite extensive research in developing
siRNA delivery systems, understanding of the cell uptake mecha-
nism of siRNA carriers is often inadequate, leading to an inability to
predict or explain transfection efﬁciencies. This is particularly
important as different materials have been proposed as siRNA-. Stolnik).
of Lincoln, Joseph Banks Lab-
om.carrying systems, including polycations such as polyethylenimine
[2], chitosan [3], dendrimers [4] and liposomes [5] and cell inter-
nalization and trafﬁcking can be inﬂuenced by the nature of the
carrier.
The present study uses an siRNA-complex based on a water
soluble piperazine-modiﬁed chitosan [6] as a model system to
investigate the relationship between gene silencing efﬁciency and
cell internalization pathways in a panel of pulmonary epithelial cell
lines, H1299, A549 and Calu-3. By employing well-established in-
hibitors of endocytosis processes in combinationwith cell imaging,
we aimed to uncover differences in the internalization pathways
and relate these to the systems’ silencing efﬁciency.
Pharmacological inhibitors were employed as a tool to decipher
the mechanisms of siRNA-polyplex cell internalization under
optimized working conditions. It is acknowledged that pharmaco-
logical inhibitors can exert multiple cellular effects, however, they
are the most often used approach to study the mechanism of
cellular trafﬁcking [7,11e16] and the current understanding of
nanoparticle trafﬁcking is based on studies using pharmacological
inhibitors. Recently, siRNA knock-down of endocytosis pathway-
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ever this approach is still less adopted in the literature and has its
own drawbacks [18]. As another alternative, we have recently
applied a new microscopy approach to study co-localization with
ﬂuorescently labelled proteins of speciﬁc endocytosis pathways
[19].
2. Materials and methods
Water-soluble piperazine chitosan derivatives were provided by
Archimedes Pharma (UK). These were synthesised and character-
ized as described previously [6]. ‘DQ39’ derivative used in this
study, N-[1-carboxymethyl-2-(1,4,4-trimethylpiperazi-1,4-dium)]
chitosan dichloride, has an Mw of 24 kDa, Mn of 39.5 kDa, and
degree of piperazine substitution (which renders the polymer
soluble in water) of 39%.
GAPDH-speciﬁc siRNA was purchased from Dharmacon (CO,
USA). Lipofectamine 2000 was purchased from Invitrogen (UK). All
other chemicals, unless otherwise stated, were obtained from
Sigma-Aldrich (UK). H1299, A549 and Calu-3 cell lines were pur-
chased from the American Type Culture Collection (USA). H1299
cells were cultured in RPMI-1640 medium supplemented with 10%
v/v foetal bovine serum (FBS), 1% v/v penicillin/streptomycin and
1% v/v L-glutamine. A549 and Calu-3 cells were cultured in Dul-
becco’s Modiﬁed Eagle’s Medium (DMEM) and Eagle’s Minimal
Essential Medium (EMEM) respectively, supplemented as above.
2.1. Formation of siRNA-polyplexes
Polyplexes were prepared in Tris-HCl buffer (10 mM, pH 7.4) by
mixing (vortexing) equal volumes of DQ39 polymer and siRNA
solutions to give a monomer:nucleotide ratio of 5:1 (unless other-
wise stated, polyplexes were used at this ratio). After mixing, pol-
yplexes were left at room temperature for 20 min before use.
2.2. In vitro silencing
Cells were seeded on 24-well plates (105 cells/well) and cultured
overnight to ~70% conﬂuency. siRNA-polyplexes (corresponding to
100 nM siRNA) were added to the cells in serum-free medium
(HBSS:HEPES pH 7.4) and incubated for up to 4 h. Samples were
then removed and replaced with fresh culture medium and cells
cultured for 44 h. GAPDH activity was analysed using the KDalert
GAPDH kit (Ambion, USA) following the supplier’s protocol, as a
commonly used knock-down assay.
2.3. Cell uptake pathway analysis
Cells were seeded on 24-well plates (105 cells/well) and cultured
overnight to ~70% conﬂuency. To quantify siRNA internalization,
siRNA-polyplexes containing Cy3-labelled siRNA (Termoﬁsher Sci-
entiﬁc, UK) (corresponding to 100 nM siRNA) were added to the
cells in serum-free medium and incubated for 5, 15, 30, 60, 120, 180
or 240 min. To establish siRNA-polyplex internalization pathways,
chemical inhibitors of endocytosis were employed (Supporting
Information, Fig. S1). Cells were pre-incubated with inhibitors for
1 h at a concentration at which high viability was preserved in
H1299 cells (Supporting Information, Fig. S2) followed by incuba-
tion with siRNA-polyplexes in serum-free medium containing the
corresponding inhibitor. Cells were then washed with PBS and
harvested by trypsin. Extracellular ﬂuorescence of polyplexes
associated with the cell surface (not internalized) was quenched
with 0.04% v/v Trypan blue (in PBS) and cells were analysed
immediately by ﬂow cytometry using a Beckman Coulter Altra ﬂow
cytometer equipped with 488 nm and 556 nm lasers to obtainforward and side scatter and read Cy3, respectively. The emitted
ﬂuorescence light was collected using 585/23 nm band pass ﬁlter;
10,000 cells were analysed per sample. Data was analysed using
Weasel Software Version 3.0.2 (The Walter and Eliza Hall Institute
of Medical Research, Melbourne Australia).
Control experiments of clathrin and caveolae inhibition studies
were conducted with known ligands for the clathrin and caveolae-
mediated pathways (FITC-transferrin at 100 mg/ml and cholera
toxin-B-subunit at 5 mg/ml, respectively) [7] (Supporting Informa-
tion, Fig. S3).
2.4. Confocal microscopy
Cells were seeded in 24-well plates onto SecureSlip™ glass
coverslips (Sigma-Aldrich, UK). Lysotracker™ Green DND-26 was
applied to cells at 50 nM for 30 min. Cells were washed three times
with PBS and ﬁxed with 4% paraformaldehyde (PFA). Hoechst dye
solution (100 mg/ml) was used for nuclei staining. Cell-containing
coverslips were mounted (using DABCO mounting medium) onto
glass slides for confocal imaging. Images were taken using a Leica
TCS SP2 system mounted on a Leica DMIRE2 inverted microscope.
2.5. Statistical analysis
Statistical comparisons for more than two data groups
employed one way analysis of variance (ANOVA) followed by
Bonferroni post-hoc test, while comparisons of two data groups
were performed using Student’s t-test. Values of p < 0.05 were
considered statistically signiﬁcant.
3. Results
Fig. 1 summarizes the physicochemical properties of model
siRNA-polyplexes, prepared at 5:1 polymer monomer:siRNA
nucleotide ratio to ensure a systemwith good colloidal stability in a
physiological ionic strength buffer (Fig. 1C) and with minimal
presence of free condensing polymer (Fig. 1A, upper panel). Gel
electrophoresis indicates that siRNA complexation occurs from low
monomer:nucleotide ratios, observed by the fading of free siRNA
bands from a 0.25:1 ratio onwards and the absence of free siRNA at
5:1 ratio (lower panel, Fig. 1A). Polyplexes possess an average
diameter of ~150 nm and surface charge of þ30 mV, which are
typical features of siRNA delivery systems [8e10].
3.1. Gene silencing and cellular uptake proﬁles
Gene silencing efﬁciencies of model siRNA-polyplexes were
evaluated and compared to their cell internalization level at cor-
responding time points (Fig. 2). There is a clear time effect in all cell
lines; longer exposure to siRNA-polyplexes resulted in an increased
cell internalization and silencing. There are no dramatic differences
in the silencing between tested cell lines at one and two hours
exposure, whilst the values for polyplex internalization for H1299
are signiﬁcantly higher compared to A549 and Calu-3 cells at the
two-hour time point, illustrating differences in polyplex uptake
between cells types. Silencing effects and internalization levels at
four hours exposure show signiﬁcant differences between the cells,
with 75% knockdown for H1299 cells, 55% for A549 and 43% for
Calu-3. Signiﬁcant cell type effect on the silencing levels is also seen
for Lipofectamine, with similar overall silencing to the model chi-
tosan system.
In addition to ﬂow cytometry, confocal microscopy was also
employed with a lysosomal marker to assess polyplex cell uptake
following 1 and 4 h exposure. Micrographs in Fig. 3AeC suggest
that in H1299 cells the level of polyplex-associated ﬂuorescence
Fig. 1. Physicochemical properties of model siRNA-polyplexes (DQ39-siRNA). A) Agarose gel electrophoresis. Lane 1: siRNA control; lanes 2e9: siRNA-polyplexes at monomer:-
nucleotide ratios of 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 2.0 and 5.0:1; lane 10: polymer control. B) Transmission electron microscopy; scale 1000 nm. C) Hydrodynamic diameter distribution,
measured by dynamic light scattering of siRNA-polyplexes in low or physiological ionic strength buffers (pH 7.4), Tris-HCl 10 mM or NaCl 150 mM.
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Fig. 2. siRNA polyplex internalization (line) and GAPDH silencing (bars) with time in a
panel of lung epithelial cell lines. Polyplexes were applied in serum-free HBSS:HEPES
medium. Cell internalization was assessed by ﬂow cytometry of Cy3-siRNA-polyplexes;
minimum 10,000 cells were analysed per sample. GAPDH activity measurements were
conducted in cells incubated in growth medium for 44 h following complex addition
and removal. Statistical comparison for uptake: A549 vs Calu-3: p < 0.0001 at all time
points; H1299 vs A549: p < 0.05 at 1 h and p < 0.0001 at all other time points. Sta-
tistical comparison for knockdown: A549 vs Calu-3: non-signiﬁcant for 1e3 h time
points and p < 0.05 at 4 h. H1299 vs A549: non-signiﬁcant for 1 and 2 h time points
and p < 0.0001 for 3 and 4 h.
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measured cell internalization in Fig. 2. Polyplex ﬂorescence appears
dispersed intracellularly, within vesicular compartments. Fig. 3A
indicates a high level of polyplex-associated ﬂorescence (red
puncta), whereby the spatial arrangement is different to the lyso-
somal marker (green). This suggests that polyplexes are predomi-
nantly distributed in the cytosol and not associated with the
lysosomes. In A549 cells, polyplex ﬂuorescence (Fig. 3B) is lower
relative to H1229 cells, which corroborates with uptake study data
in Fig. 2. The spatial arrangement of polyplex and lysosome-
associated ﬂuorescence again indicates that polyplexes do not co-
locate with the lysosomes. With Calu-3 cells (Fig. 3 Ci-iii), growth
on glass substrate as ‘cell islands’ (despite sub-conﬂuence) makes
the interpretation of confocal microscopy data difﬁcult.3.2. Cell internalization pathways
Fig. 4 summarizes the effects of endocytosis inhibitors on cell
internalization of siRNA-polyplexes and reveals clear cell type-
dependent differences. In H1299 cells, treatments with caveolae
pathway inhibitors, genistein or MbCD, resulted in a statisticallysigniﬁcant reduction of siRNA-complex uptake, relative to the un-
treated control, whilst concavalin-A (clathrin pathway inhibitor)
did not exert a statistically signiﬁcant effect. Interestingly, genistein
and MbCD effects are notably different. Genistein blocks caveolae-
dependent endocytosis by acting as an inhibitor of tyrosine kinase,
whilst MbCD is a sterol-binding compound that sequesters
cholesterol from the cell membrane, affecting lipid rafts and
caveolae-dependent pathway (Supporting Information, S1), hence
affecting the caveolar pathway by different mechanisms. The rea-
sons for genistein-MbCD apparent discrepancy are not clear pres-
ently. We, however, noticed a relativelymoderate effect of genistein
on H1299 internalization of the caveolae pathway speciﬁc ligand,
cholera toxin B, (Supporting Information, Fig. S3B).
In A549 cells, both clathrin and caveolae endocytosis inhibitors
display signiﬁcant effects: concavalin-A reduces cell internalization
to approximately 50% of the untreated control, with caveolae-
dependent pathway inhibition by genistein and exposure to
MbCD reducing internalization to approximately 35% and 10%,
respectively. Calu-3 cells exhibited a marked reduction in polyplex
uptake (approximately 20% of untreated control) on inhibition of
the clathrin pathway (concavalin-A treatment), whilst genistein or
MbCD inhibition of caveolae-dependent pathway suppressed the
uptake to a signiﬁcantly lesser extent (to around 80% and 70% of the
untreated control, respectively). Polyplex cell uptake in the pres-
ence of dynasore, an inhibitor of both clathrin and caveolae-
mediated endocytosis, is reduced to 40e50% of untreated control
in all cell lines, while cytochalasin D, an inhibitor of macro-
pinocytosis, displays a small, although statistically signiﬁcant effect.
Next, we investigated whether the relatively low levels of
silencing in A549 and Calu-3 cells, are a consequence of the nature
of endocytosis that predominately involves the clathrin route. To
this end, gene silencing was conducted in the presence of the
endosomolytic agent, chloroquine (Fig. 4, inset). In Calu-3 cells
chloroquine treatment signiﬁcantly increased the silencing efﬁ-
ciency, from 33% to 66% of the control, whereas no signiﬁcant in-
ﬂuence was observed in A549 cells. Data thus indirectly point to a
principally clathrin-mediated internalization of siRNA polyplexes
by Calu-3 cells, whereby the silencing efﬁciency is enhanced by the
endosomolytic action of chloroquine.4. Discussion
Effective siRNA delivery into target cells is the main barrier to
translation of siRNA therapeutics into the clinic. Cell trafﬁcking
pathways of siRNA are still not clearly understood to inform the
formulation development [15,20]. In this study, we investigated the
mechanisms by which siRNA-polyplexes enter different types of
Fig. 3. Confocal microscopy images of siRNA-polyplex internalization in A) H1299, B) A549 and C) Calu-3 cells. Cy3-labelled siRNA (red) complexes with DQ39 at 5:1 mono-
mer:nucleotide ratio were incubated with cells for i) 1 h or ii) 4 h iii) z-stack of siRNA-polyplexes internalization at 4 h. Nuclei appear in blue, lysosomal compartments stained with
LysoTracker Green (green). Scale bar: 20 mm (A and B) and 25 mm (C). (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of
this article.)
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relationship between cell entry pathways and silencing efﬁciency.
Of the selected lung epithelial cell lines, H1299 cultures are
often used to report siRNA silencing for lung application systems
(considered ‘suitable transfection hosts’) [8,21,22]. Calu-3 and
A549 cell lines are signiﬁcantly less utilised in these studies, despite
appreciation that they offer a more representative model of the
airway epithelium [23e25]. The lung is a prominent target for local,
non-invasive siRNA delivery for lung cancers and other diseases
such as chronic obstructive pulmonary disease, asthma and respi-
ratory syncytial virus [26e28], highlighting the relevance of this
study.
Our data demonstrate a cell type-dependent level of siRNA-
polyplex internalization, trafﬁcking and silencing efﬁciency in
different cells. The literature highlights a complex relationshipbetween siRNA polyplex cell uptake and silencing efﬁciency [20]
and the data in Fig. 2 conﬁrms this complexity.
Contribution of both clathrin and caveolin-dependent pathways
in the internalization of siRNA-polyplexes is apparent in the
A549 cell line, in line with our previous study for DNA-polyplexes,
which also showed involvement of microtubules and actin ﬁla-
ments (conﬁrming vesicular intracellular transport) [29]. The data
rules out a prominent role of dynamin-independent endocytosis
(macropinocytosis) in all tested epithelial cell types, as judged from
the small reduction in polyplex cell uptake following treatment
with cytochalasin D (~10%) and substantial (~50%) reduction with
dynasore, an inhibitor that plays an essential role in the ‘release’ of
the formed caveolin- and clathrin-coated vesicles [30]. This is in
disagreement with a recent study in HeLa cells whereby down-
regulation of macropinocytosis components (Cdc42 and Rac1)
Fig. 4. Cell internalization of siRNA-polyplexes in the presence of pharmacological endocytosis inhibitors. Inhibitors were applied to the cells for 1 h before polyplex addition
(corresponding to 100 nM siRNA). Cells were treated with polyplexes for 2 h in serum-free medium containing concanavalin-A 100 mg/ml, dynasore 100 mM, genistein 100 mM,
MbCD 4 mM, cytochalasin D 2 mg/ml. Comparisons relative to control, untreated cells. Inset: GAPDH knockdown with siRNA-polyplexes in A549 and Calu-3 cells in the presence of
chloroquine. Polyplexes were incubated with the cells in serum-free medium or medium containing chloroquine for 4 h, with further 44 h incubation in medium before analysis.
Data shown as the mean ± SD (n ¼ 3 inhibitor study and n ¼ 6 chloroquine study). ‘ns’ not signiﬁcant; * p < 0.05; *** p < 0.001,**** p < 0.0001.
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particles by ~80%, whereas inhibition of clathrin and caveolae-
dependent pathways had little impact on cell entry [15]. Howev-
er, another recent study utilizing HeLa cells reported a signiﬁcant
reduction in cell uptake of DNA-loaded lipid nanoparticles
following inhibition of clathrin-mediated and clathrin-
independent endocytosis, suggesting the involvement of vesicle-
mediated internalization [31]. In the DNA-delivery ﬁeld, a study
comparing the transfection efﬁciency of chitosan-alginate poly-
plexes in diverse cell types reported that the uptake route is
dependent on the cell line and has signiﬁcant consequences on
gene transfection efﬁciencies. Cell uptake by the clathrin pathway
was suggested to be responsible for successful gene expression in
293T and Cos7 cells (due to the ‘proton sponge’ endosomal escape),
whilst caveolin-mediated endocytosis in CHO cells resulted in
vesicle-entrapped polyplexes that become transfection-
incompetent [32].
In Calu-3 cells, clathrin pathway inhibition by concavalin-A
resulted in notable reduction of polyplex uptake (~80%), while a
much lower effect was apparent on inhibition of caveolae-
dependent pathway (~20% and ~30% reduction for genistein and
MbCD, respectively) e markedly lower compared to A549 and
H1299 cells, therefore pointing to a considerable involvement of
non-clathrin/caveolin internalization. Lysosomal disruption in
Calu-3 cells enhanced gene silencing, an observation not apparent
in A549 cells. The data therefore suggests that piperazine-
substituted chitosans follow a predominantly clathrin-mediated
entry route in Calu-3 cells and may not demonstrate an efﬁcient
endosomal escape. Our ﬁndings also imply that the incorporation
of an endosomolytic component into the siRNA delivery system
where the dominant cellular internalization pathway involves
clathrin may be beneﬁcial to augment the silencing efﬁciency, but
such functionality could be purposeless in non-clathrin cell inter-
nalization pathways.
This study shows that model polyplexes exhibited the highest
silencing effect in H1299 cells, whereby a predominantly caveolin-
mediated internalization was apparent. Interestingly, in control
experiments we noticed that transferrin internalization (clathrinpathway marker) by H1299 cells was relatively low, in both extent
and rate (Supporting Information, Fig. S3). H1299 cells are reported
to have a homozygous partial deletion of the TP53 gene and do not
express the tumour suppressor p53 protein [33]. The most
commonly used cell lines in siRNA transfection studies, such as
H1299, HeLa and CHO cells, all considered as ‘suitable transfection
hosts’, have either low or non-functioning p53 expression [34,35],
whereas A549 and Calu-3 cell lines, as more representative culture
models of the ‘normal’ lung, both express wild type p53 [36,37].
There is a suggestion that the p53 protein is involved in the regu-
lation of clathrin endocytosis; p53 knockdown delays the uptake of
epidermal growth factor receptor (EGFR) e one of the most char-
acterized receptors to study the mechanisms of clathrin-mediated
endocytosis [38]. Further studies are required to conﬁrm the p53-
clathrin connection, however if cell lines with low or non-
functioning p53 expression indeed lack effective clathrin-
mediated endocytosis, with ‘alternative’ non-clathrin uptake
pathways assuming a predominant function, this would be an
important parameter to understand in relation to the design of
siRNA delivery systems. Furthermore, establishing its relevance to
the in vivo situation and lung cancer models [39] would be ad-
vantageous for in vitro e in vivo data translation.
Overall, our study highlights the importance of cell model se-
lection, even in closely related cell types, on understanding of the
silencing efﬁcacy of siRNA delivery systems. Furthermore, it em-
phasises that knowledge on cell trafﬁcking processes is essential in
deciding the design parameters of siRNA delivery systems.Acknowledgement
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